[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor-immune-microenvironment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor-immune-microenvironment":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100618444","association-of-bal-fluid-t-cell-immune-activity-with-tumor-pd-l1-expression-and-its-prognostic-value-a-prospective-observational-study-100618444",false,"NCT07331701","Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study","Inclusion Criteria:\n\n* Adults aged 19 years or older\n* Patients with suspected or histologically confirmed stage IV lung cancer based on clinical and radiologic findings\n* Scheduled to undergo clinically indicated bronchoscopy with bronchoalveolar lavage as part of routine clinical care\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Receipt of treatment for acute lower respiratory tract infection (including pneumonia or fungal infection) within 4 weeks prior to bronchoscopy\n* History of solid organ transplantation or hematopoietic stem cell transplantation\n* Current use of systemic immunosuppressive therapy\n* Current or planned use of biologic immunomodulatory agents\n* Known autoimmune disease requiring systemic immunosuppressive treatment\n* Pregnant women\n* Patients with recurrent stage IV lung cancer after prior definitive therapy","ALL","19 Years",{"count":18,"type":19},60,"ESTIMATED","2 Years","OBSERVATIONAL","This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in predicting clinical outcomes in patients with advanced lung cancer. Although tumor PD-L1 expression measured on tissue biopsies is widely used to guide immunotherapy decisions, its predictive value is limited by spatial heterogeneity and sampling variability. By analyzing activated, exhausted, and regulatory T-cell populations in bronchoalveolar lavage fluid and examining their association with tissue-based tumor PD-L1 expression, this study seeks to determine whether combining local immune biomarkers with PD-L1 expression improves the prediction of treatment response and survival in patients receiving standard-of-care systemic therapy.",[24,25],"Lung Neoplasms","Tumor Immune Microenvironment",[27,28,29,30,31,25,32,33,34,35],"Bronchoalveolar Lavage Fluid","Tumor-Infiltrating T Lymphocytes","Programmed Cell Death 1 Ligand 1","Immune Checkpoint Inhibitors","Flow Cytometry","Treatment Response","Progression-Free Survival","Overall Survival","Predictive Biomarkers","NOT_YET_RECRUITING","2025-12-29",{"date":39,"type":40},"2026-01-12","ACTUAL",{"date":42,"type":19},"2026-01",{"date":44,"type":19},"2027-12-31",{"name":46,"class":47},"Seoul National University Hospital","OTHER"]